Please wait while we load the requested 10-Q report or click the link below:
AEGERION PHARMACEUTICALS ANNOUNCES
SECOND QUARTER 2015 FINANCIAL RESULTS
- Company records $64.2 million in total net product sales -
- JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. -
- Company reiterates 2015 total net product sales guidance of between $205 and $235 million -
Cambridge, MA, August 5, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the second quarter of 2015.
|||Aegerion recorded $57.1 million in net product sales of JUXTAPID® (lomitapide) capsules in the second quarter of 2015, representing growth of approximately 59% over the second quarter of 2014. 96% of JUXTAPID net product sales in the second quarter of 2015 were from prescriptions written in the United States.|
|||Aegerion recorded $7.1 million in net product sales of MYALEPT® (metreleptin for injection) in the second quarter of 2015, all of which were from prescriptions written in the United States. As of July 31, 2015, 68 generalized lipodystrophy (GL) patients were active on commercial therapy.|
|||Aegerions cash increased by $15.2 million in the second quarter of 2015.|
|||The Company is on track with its plan to file a Japanese NDA for lomitapide in adult HoFH patients late 2015 or early 2016. The Company anticipates a nine month review period as a result of lomitapides orphan drug status.|
Chief Executive Officer Sandford D. Smith commented, Aegerion continued to show good progress during the second quarter in key areas of the business, including growth in number of patients on therapy for both of our products. We believe we are on track to deliver strong results; however, as we navigate through the early days of the PCSK9 inhibitor launches, we are maintaining our prior guidance for the year. We remain focused on building a fully integrated, leverageable and risk-diversified company to deliver therapies to patients with rare diseases.
With the objective of maximizing the value of our current assets, we have focused attention and resources on expanding the opportunities for both MYALEPT and JUXTAPID by prioritizing investments in research and development to support the
The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Wednesday, August 5, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aegerion Pharmaceuticals, Inc..